Research on the epigenetic modification of pancreatic cancer vaccine.

Wei Cao, Guoxiong Zhou, J. Qiu, Liangfeng Xu, Xiaoling Ding, Haifeng Zhang, Xiaorong Zhou

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of MHC-II that may lead to immune evasion. Here, we tried to prepare pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic lymphocytes (CTL), promote Th1-type cells mediated secretion of cytokines IFN-gamma and IL-2 while inhibiting Th2-type cells mediated secretion of IL-4, and inhibit the secretion of TGF-beta. Generally, the epigenetically modified vaccine could enhance the body's anti-tumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)272-277
Number of pages6
JournalHepato-Gastroenterology
Volume61
Issue number130
StatePublished - 2014

Fingerprint

Cancer Vaccines
Pancreatic Neoplasms
Epigenomics
Vaccines
Research
Immune Evasion
Active Immunotherapy
Neoplasms
Th2 Cells
Th1 Cells
Inbred C57BL Mouse
Interleukin-4
Transforming Growth Factor beta
Interleukin-2
Lymphocytes
Cytokines
T-Lymphocytes
Antigens
Cell Line
Genes

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Cao, W., Zhou, G., Qiu, J., Xu, L., Ding, X., Zhang, H., & Zhou, X. (2014). Research on the epigenetic modification of pancreatic cancer vaccine. Hepato-Gastroenterology, 61(130), 272-277.

Research on the epigenetic modification of pancreatic cancer vaccine. / Cao, Wei; Zhou, Guoxiong; Qiu, J.; Xu, Liangfeng; Ding, Xiaoling; Zhang, Haifeng; Zhou, Xiaorong.

In: Hepato-Gastroenterology, Vol. 61, No. 130, 2014, p. 272-277.

Research output: Contribution to journalArticle

Cao, W, Zhou, G, Qiu, J, Xu, L, Ding, X, Zhang, H & Zhou, X 2014, 'Research on the epigenetic modification of pancreatic cancer vaccine.', Hepato-Gastroenterology, vol. 61, no. 130, pp. 272-277.
Cao W, Zhou G, Qiu J, Xu L, Ding X, Zhang H et al. Research on the epigenetic modification of pancreatic cancer vaccine. Hepato-Gastroenterology. 2014;61(130):272-277.
Cao, Wei ; Zhou, Guoxiong ; Qiu, J. ; Xu, Liangfeng ; Ding, Xiaoling ; Zhang, Haifeng ; Zhou, Xiaorong. / Research on the epigenetic modification of pancreatic cancer vaccine. In: Hepato-Gastroenterology. 2014 ; Vol. 61, No. 130. pp. 272-277.
@article{c6a46651883d41c68fa06d90a31ef942,
title = "Research on the epigenetic modification of pancreatic cancer vaccine.",
abstract = "Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of MHC-II that may lead to immune evasion. Here, we tried to prepare pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic lymphocytes (CTL), promote Th1-type cells mediated secretion of cytokines IFN-gamma and IL-2 while inhibiting Th2-type cells mediated secretion of IL-4, and inhibit the secretion of TGF-beta. Generally, the epigenetically modified vaccine could enhance the body's anti-tumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.",
author = "Wei Cao and Guoxiong Zhou and J. Qiu and Liangfeng Xu and Xiaoling Ding and Haifeng Zhang and Xiaorong Zhou",
year = "2014",
language = "English (US)",
volume = "61",
pages = "272--277",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "130",

}

TY - JOUR

T1 - Research on the epigenetic modification of pancreatic cancer vaccine.

AU - Cao, Wei

AU - Zhou, Guoxiong

AU - Qiu, J.

AU - Xu, Liangfeng

AU - Ding, Xiaoling

AU - Zhang, Haifeng

AU - Zhou, Xiaorong

PY - 2014

Y1 - 2014

N2 - Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of MHC-II that may lead to immune evasion. Here, we tried to prepare pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic lymphocytes (CTL), promote Th1-type cells mediated secretion of cytokines IFN-gamma and IL-2 while inhibiting Th2-type cells mediated secretion of IL-4, and inhibit the secretion of TGF-beta. Generally, the epigenetically modified vaccine could enhance the body's anti-tumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.

AB - Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of MHC-II that may lead to immune evasion. Here, we tried to prepare pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic lymphocytes (CTL), promote Th1-type cells mediated secretion of cytokines IFN-gamma and IL-2 while inhibiting Th2-type cells mediated secretion of IL-4, and inhibit the secretion of TGF-beta. Generally, the epigenetically modified vaccine could enhance the body's anti-tumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84902683027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902683027&partnerID=8YFLogxK

M3 - Article

C2 - 24901123

AN - SCOPUS:84902683027

VL - 61

SP - 272

EP - 277

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 130

ER -